Successful Completion of Phase I/IIa Clinical Study of VAC-3S Immunotherapeutic Vaccine
Published: Monday, December 03, 2012 Last Updated: Monday, December 03, 2012
Interim results of the phase I/IIa clinical study revealed a good safety and tolerability profile for the VAC-3S immunotherapeutic vaccine, which was the primary endpoint of the study performed in two AP-HP reference clinical centers in Paris, France, at Pitié Salpêtrière and Cochin Hospitals.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.